Raymond James Financial’s Traws Pharma TRAW Stock Holding History

Raymond James Financial’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-102	Closed	-$151	–	6877
2025 Q2	$151	Buy	+102	New	+$163	﹤0.01%	6810

Other funds holding TRAW

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial's TRAW Position: Q3 2025 in Review

Raymond James Financial sold out of Traws Pharma (TRAW) in Q3 2025, closing a stake of 102 shares — an estimated $151 sold.

Raymond James Financial first reported a position in TRAW in Q2 2025 and held it in 1 quarter. The position peaked at $151 in Q2 2025. 18 funds tracked by Wall St. Rank hold TRAW as of Q3 2025.

Raymond James Financial reported no remaining Traws Pharma position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 102 Traws Pharma shares in Q3 2025, an estimated $151.
Raymond James Financial first reported a position in Traws Pharma in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Traws Pharma position peaked at $151 in Q2 2025.
18 funds tracked by Wall St. Rank held Traws Pharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.